首页> 美国卫生研究院文献>Oncology Letters >Clinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas based on the 2011 IASLC/ATS/ERS classification
【2h】

Clinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas based on the 2011 IASLC/ATS/ERS classification

机译:基于2011 IASLC / ATS / ERS分类的肺侵袭性腺癌中转移相关蛋白1表达及其与血管生成的关系的临床病理和预后意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Based on previous findings regarding the angiogenic activities and prognostic roles of metastasis-associated protein 1 (MTA1) in early-stage non-small cell lung cancer, the clinicopathological and prognostic significance of MTA1 protein expression, and its correlation with angiogenesis in lung invasive adenocarcinoma, were further assessed in the present study, according to the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. High protein expression levels of MTA1 were commonly observed in patients with lung invasive adenocarcinoma, and were significantly correlated with tumor size (P=0.030), lymph node metastasis (P=0.021) and microvessel density (P=0.015). Survival analysis demonstrated that patients with high protein expression levels of MTA1 exhibited significantly shorter five-year disease-free and overall survival than those patients whose protein expression levels of MTA1 were low (24.5% vs. 48.7%, P=0.001, and 34.7% vs. 59.2%, P=0.005, respectively). In addition, Cox regression multivariate analysis demonstrated that high protein expression levels of MTA1 significantly correlated with unfavorable five-year disease-free survival (P=0.024). These findings indicate that MTA1 protein expression may possess clinical potential as an indicator of progressive phenotype. Therefore, MTA1 is a promising prognostic predictor to identify subgroups of patients with high risk of relapse, and a potentially novel therapeutic target for antiangiogenesis in patients with lung invasive adenocarcinoma.
机译:基于转移相关蛋白1(MTA1)在早期非小细胞肺癌中的血管生成活性和预后作用的先前发现,MTA1蛋白表达的临床病理学和预后意义及其与肺浸润性腺癌的血管生成相关性根据2011年国际肺癌研究协会/美国胸腔学会/欧洲呼吸学会分类,在本研究中进一步评估了。 MTA1的高蛋白表达水平通常在肺浸润性腺癌患者中观察到,并且与肿瘤大小(P = 0.030),淋巴结转移(P = 0.021)和微血管密度(P = 0.015)显着相关。生存分析表明,与MTA1蛋白表达水平较低的患者相比,MTA1蛋白表达水平较高的患者的五年无病生存期和总体生存期明显短(24.5%比48.7%,P = 0.001和34.7%)。 vs. 59.2%,P = 0.005)。此外,Cox回归多元分析表明,MTA1的高蛋白表达水平与不良的五年无病生存率显着相关(P = 0.024)。这些发现表明,MTA1蛋白表达可能具有作为进行性表型指标的临床潜力。因此,MTA1是确定有高复发风险的患者亚组的有希望的预后指标,也是肺浸润性腺癌患者抗血管生成的潜在新治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号